Goldman Sachs’s VanEck Biotech ETF BBH Stock Holding History

Goldman Sachs’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,900	Closed	-$239K	–	6655
2017 Q2	$239K	Buy	+1,900	New	+$229K	﹤0.01%	5673

Other funds holding BBH

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

CCA

Conservest Capital Advisors Wynnewood, Pennsylvania $1.1B AUM 16.5% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BFG

Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return

PPWM

Paragon Private Wealth Management Lexington, Kentucky $320M AUM 23.48% 1-Year Est. Return

Goldman Sachs's BBH Position: Q1 2026 in Review

Goldman Sachs held its VanEck Biotech ETF (BBH) position steady in Q1 2026 at 102,079 shares worth $19.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2469.

Goldman Sachs first reported a position in BBH in Q2 2013 and has held it in 44 quarters since. The position peaked at $162M in Q2 2015. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

Goldman Sachs held 102,079 shares of VanEck Biotech ETF worth $19.2M as of Q1 2026.
Goldman Sachs left its VanEck Biotech ETF share count unchanged in Q1 2026.
VanEck Biotech ETF made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2469 holding.
Goldman Sachs first reported a position in VanEck Biotech ETF in Q2 2013 and has held it in 44 quarters since.
Goldman Sachs's VanEck Biotech ETF position peaked at $162M in Q2 2015.
112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.